Wednesday, December 03, 2025 NCI MyeloMATCH Presentations at ASH 2025MyeloMATCH opened in mid-2024, and the first results from the trial are being presented at the 2025 ASH Annual Meeting (December 6-9, 2025; Orlando, FL). There will be an oral presentation and five posters at the meeting, please see the detailed information here >The MyeloMATCH screening trial and five treatment trials of targeted combination agents are open for patient enrollment, with more treatment trials planned. The unique design of MyeloMATCH allows patients to be followed along the course of their disease, with possible additional treatment options available to them depending on further genetic testing. The screening study ALC.7 (MYELOMATCH ǀ NCT05564390) and two treatment trials are now open in Canada >
